(Q35819325)

10 August 2017

1 reference

title

Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant? (English)

1 reference

chronic lymphocytic leukemia

10 August 2017

0 references

1 reference

3

Champlin RE

1 reference

10 August 2017

4

Khouri IF

1 reference

10 August 2017

2

Keating MJ

1 reference

10 August 2017

Jabbour E

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

Bone Marrow Transplantation

10 August 2017

published in

1 reference

10 August 2017

volume

34

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

289-297

1 reference

Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

B-cell chronic lymphocytic leukemia: a bird of a different feather

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

Cellular and clinical pharmacology of fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

Chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Hematopoietic stem cell transplantation for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leuk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

In vivo purging with rituximab prior to collection of stem cells for autologous transplantation in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

In vivo 'Purging' of residual disease in CLL with Campath-1H

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Myelodysplasia and acute leukemia after autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Different clinical value of minimal residual disease after autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Chronic lymphocytic leukaemia: proposals for a revised prognostic staging system. Report from the International Workshop on CLL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Allogeneic haematopoietic transplantation for Richter's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

The usefulness of high dose (7-10mci) gallium (67Ga) scanning to diagnose Richter's transformation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704593

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704593

1 reference

Dimensions Publication ID

10 August 2017

1044690419

0 references

1 reference